- Home
- GNK vs COAG Comparison
GNK vs COAG Comparison
Compare GNK & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNK | COAG |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GNK | COAG |
|---|---|---|
| Price | $27.15 | $43.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 573.7K | 286.4K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $342,054,000.00 | N/A |
| Revenue This Year | $21.15 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | $46.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.56 | $27.47 |
| 52 Week High | $27.76 | $55.42 |
Technical Indicators
Market Signals| Indicator | GNK | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 43.34 |
| Support Level | $22.78 | $42.65 |
| Resistance Level | $27.76 | $53.01 |
| Average True Range (ATR) | 0.91 | 3.78 |
| MACD | 0.04 | -1.12 |
| Stochastic Oscillator | 74.04 | 13.20 |
Price Performance
Historical ComparisonAbout GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.